Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model
Naoya Uchida(National Heart Lung and Blood Institute), John F. Tisdale(National Institutes of Health), Leanne Lanieri(Fate Therapeutics (United States)), Xiaolin Wu(Leidos (United States)), Nathaniel S. Linde(National Institutes of Health), Alexander Berg(National Institutes of Health), Aylin Bonifacino(National Institutes of Health), Cynthia E. Dunbar(National Institutes of Health), Selami Demirci(National Heart Lung and Blood Institute), Lisa Olson(Fate Therapeutics (United States)), Ling Su(Chinese Academy of Sciences), Anjali Bhat(Fate Therapeutics (United States)), Rahul Palchaudhuri(Somerville Hospital), Paula Germino-Watnick(National Institutes of Health), Rebecca Chu(National Institutes of Health), Ulana Stasula(National Institutes of Health), So Gun Hong(National Institutes of Health), Robert E. Donahue(National Institute of Diabetes and Digestive and Kidney Diseases), Malikiya Hinds(National Institutes of Health), Megan D. Hoban(Fate Therapeutics (United States)), Xiong Liu(Xiamen University), Anh Tuấn Lê(National Institutes of Health), Allen E. Krouse(National Institutes of Health), Kirk Bertelsen(Fate Therapeutics (United States)), Bindu Bennet(Fate Therapeutics (United States))
Cited by 46
Related Papers
Gene therapy comes of age
|Science|2018|1.4k
Antimicrobial Properties of Zeolite-X and Zeolite-A Ion-Exchanged with Silver, Copper, and Zinc Against a Broad Range of Microorganisms
|Applied Biochemistry and Biotechnology|2013|173
Boron and Poloxamer (F68 and F127) Containing Hydrogel Formulation for Burn Wound Healing
|Biological Trace Element Research|2015|114
Gene therapy for sickle cell disease: An update
|Cytotherapy|2018|114